


**Amendments to the Claims**

Please amend the claims as follows:

1. (Currently amended) A compound of the formula (I):



wherein

$R^1$  is hydrogen, halogen, hydroxy, amino,  $-\text{CHF}_2$ ,  $-\text{CF}_3$ , or  $-\text{NHSO}_2\text{CH}_3$ ;

$R^2$ ,  $R^3$ , and  $R^4$  are each independently selected from the group consisting of:

hydrogen;

halogen;

$-(\text{C}_1\text{-C}_4)\text{alkyl}$ ;

$-\text{CF}_3$ ;

amino,

nitro;

$-(\text{CH}_2)_p\text{OR}^{10}$ ;

$-(\text{CH}_2)_h\text{CN}$ ;

$-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$ ;

$-\text{C}(\text{O})\text{OR}^{16}$ ;

$-\text{NHC}(\text{O})\text{R}^{13}$ ;

$-\text{O}(\text{CH}_2)_o\text{Y}$ ;

$-\text{SCH}_3$ ;

$-\text{SO}_2\text{R}^{14}$ ;

N-morpholino;

N-piperazine or N-piperazine substituted with  $(\text{C}_1\text{-C}_4)\text{alkyl}$ ;

N-pyrrolidine or N-pyrrolidine substituted with  $-(\text{CH}_2)_p\text{OH}$ ;


N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with  $-\text{CF}_3$ , nitro, amino, halogen, hydroxy,  $(\text{C}_1\text{-C}_4)$  alkyl,  $(\text{C}_1\text{-C}_4)$ alkoxy or  $-\text{NHSO}_2\text{CH}_3$ ; and

piperidine or piperidine substituted on the nitrogen with  $-\text{C}(\text{O})(\text{C}_1\text{-C}_4)$  alkyl;

or  $\text{R}^2$  and  $\text{R}^3$  may, together with the phenyl ring to which they are attached, form a naphthalene (benzo-fused ring) of the structure:



$\text{R}^5$ ,  $\text{R}^6$  and  $\text{R}^8$  are hydrogen;

$\text{R}^7$  and  $\text{R}^9$  are each independently hydrogen or hydroxy;

$\text{R}^{10}$  is hydrogen,  $(\text{C}_1\text{-C}_4)$ alkyl,  $-(\text{CF}_2)_n\text{CHF}_2$ ,  $-(\text{CH}_2)_q\text{NR}^{17}\text{R}^{18}$ ,  $-(\text{CH}_2)_q\text{O}(\text{C}_1\text{-C}_4)$  alkyl, pyrrolidine, or phenyl;

which pyrrolidine may be optionally substituted on the nitrogen with  $\text{C}_1\text{-C}_4$  alkyl.

$\text{R}^{11}$  and  $\text{R}^{12}$  are each independently hydrogen or  $(\text{C}_1\text{-C}_4)$ alkyl;

$\text{R}^{13}$  is  $(\text{C}_1\text{-C}_4)$ alkyl, cyclopropyl or  $-(\text{CH}_2)\text{-OR}^{19}$ ;

$\text{R}^{14}$  is  $(\text{C}_1\text{-C}_4)$ alkyl,  $-\text{NR}^{20}\text{R}^{21}$ , N-pyrrolidine, phenyl, or  $-\text{CF}_3$ ;

$\text{R}^{16}$ ,  $\text{R}^{17}$ ,  $\text{R}^{18}$ ,  $\text{R}^{19}$ ,  $\text{R}^{20}$ , and  $\text{R}^{21}$  are each independently hydrogen or  $\text{C}_1\text{-C}_4$  alkyl;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

q is 1, 2, or 3;

t is 0 or 1;

Y is morpholine, pyrrolidine, or pyrrolidine substituted on the nitrogen by  $(\text{C}_1\text{-C}_4)$ alkyl;

~~and the pharmaceutically acceptable salts thereof~~ or a pharmaceutically acceptable salt thereof.

2. (Currently amended) The compound according to **Claim 1**, wherein

$\text{R}^2$  is hydrogen,  $\text{C}_1\text{-C}_4$  alkyl, or phenyl;

$\text{R}^3$  is hydrogen or hydroxy;

$\text{R}^4$  is hydrogen, halogen, nitro, cyano,  $-\text{CF}_3$ ,  $-(\text{CH}_2)_p\text{OR}^{10}$ , or  $-\text{SO}_2\text{R}^{14}$ ;

p is 0;

R<sup>10</sup> is -CHF<sub>2</sub>;

R<sup>14</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl; -CF<sub>3</sub>; or -NR<sup>20</sup>R<sup>21</sup>,

~~and the pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof.~~

3. (Currently amended) The compound according to **Claim 2** wherein R<sup>4</sup> is nitro;  
~~and the pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof.~~

4. (Original) The compound according to **Claim 3** wherein R<sup>2</sup> and R<sup>3</sup> are hydrogen.

5. (Currently amended) The compound according to **Claim 2** wherein R<sup>2</sup> is hydrogen;  
R<sup>3</sup> is hydroxy; and R<sup>4</sup> is hydrogen;  
~~and the pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof.~~

6. (Original) The compound according to **Claim 1**, which is selected from the group consisting of:

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-cyanophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;


7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(2-methyl-4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt;

(S)-7-Phenyl-isoquinoline-5-sulfonic acid [2-(3-hydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide, mesylate salt;

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 1, dihydrochloride salt; and

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-ethyl]-amide isomer 2, dihydrochloride salt.

7. (Currently amended) A compound of the formula:



wherein R<sup>1</sup> is hydrogen, halogen, hydroxy, amino, -CHF<sub>2</sub> or -NHSO<sub>2</sub>CH<sub>3</sub>;

R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently:

hydrogen;

halogen;

-(C1-C4)alkyl;

-CF<sub>3</sub>;

amino;

nitro;

-(CH<sub>2</sub>)<sub>p</sub>OR<sup>10</sup>;

-(CH<sub>2</sub>)<sub>n</sub>CN;

-C(O)NR<sup>11</sup>R<sup>12</sup>;

-C(O)OR<sup>11</sup>;

-NHC(O)R<sup>13</sup>;

-O(CH<sub>2</sub>)<sub>k</sub>Y;

-SCH<sub>3</sub>;

-SO<sub>2</sub>R<sup>14</sup>;

N-morpholino;


N-piperazine or N-piperazine substituted with (C1-C4)alkyl;

N-pyrrolidine or N-pyrrolidine substituted with -(CH<sub>2</sub>)<sub>p</sub>OH;

N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with  $-\text{CF}_3$ , nitro, amino, halogen, hydroxy, (C1-C4) alkyl, (C1-C4)alkoxy or  $-\text{NHSO}_2\text{CH}_3$ ;  
 piperidine or piperidine substituted on the nitrogen with  $-\text{C}(\text{O})(\text{C1-C4})$  alkyl;  
 or wherein  $\text{R}^2$  and  $\text{R}^3$  may together with the phenyl ring of formula I form a naphthalene (benzo-fused ring) of the structure:



$\text{R}^5$ ,  $\text{R}^6$  and  $\text{R}^8$  are hydrogen;

$\text{R}^7$  and  $\text{R}^9$  are each independently hydrogen or hydroxy;

$\text{R}^{10}$  is hydrogen, (C1-C4)alkyl,  $-(\text{CF}_2)_n\text{CHF}_2$ ,  $-(\text{CH}_2)_m\text{NR}^{11}\text{R}^{12}$ ,  $-(\text{CH}_2)_o(\text{C1-C4})$ alkyl, or phenyl;

$\text{R}^{11}$  and  $\text{R}^{12}$  are each independently hydrogen or (C1-C4)alkyl;

$\text{R}^{13}$  is (C1-C4)alkyl, cyclopropyl or  $-(\text{CH}_2)_p\text{R}^{11}$ ;

$\text{R}^{14}$  is (C1-C4)alkyl,  $-\text{NR}^{11}\text{R}^{12}$ , N-pyrrolidine, phenyl, or  $-\text{CF}_3$ ;

m is 0, 1, 2, or 3;

n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

Y is morpholine, pyrrolidine or pyrrolidine substituted on the nitrogen by (C1-C4)alkyl;

~~and the pharmaceutically acceptable salts thereof or a pharmaceutically acceptable salt thereof.~~

8. (Previously presented) A compound selected from the group consisting of:

7-phenyl-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-difluoromethylphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-fluorophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-methylsulfonamido)- isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; and

7-(4-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-hydroxy-phenyl)-isoquinoline-5-sulfonic acid {2-[3-(4-nitro-phenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; and

7-phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitro-phenyl)-propylamino]-ethyl}-amide, dimesylate.

9. (Previously presented) A pharmaceutical composition comprising a compound of **Claim 1**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

10. (Cancelled)

11. (Cancelled)